AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer

Recruitingn/aAges 18 Years - 60 YearsFemaleShengjing Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The incidence of breast cancer in Chinese women has increased year by year, and luminal A breast cancer commonly occurs in early-stage and postmenopausal women. This type of breast cancer is not sensitive to chemotherapy, although it has a low mortality rate and distant metastasis rate. Studies have shown that luminal A breast cancer is sensitive to endocrine therapy. Patients with breast cancer who undergo excision should be followed up and their prognosis should be monitored regularly. At present, imaging detection is mainly used in the conventional follow-up of breast cancer, but the cost of many imaging examinations is high, so a cost-effective examination is urgently needed. Recent studies have found that circulating tumor cells can be used as a new type of tumor molecular marker, which can be used to diagnose tumors, judge the prognosis and monitor the efficacy by detecting the nu

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * estrogen receptor (โ‰ฅ 10%), progesterone receptor (โ‰ฅ 10%) and epidermal growth factor receptor 2 negative; * proliferation index Ki-67 \< 20%; * no lymph node metastasis; * systemic therapy (chemotherapy, radiotherapy and endocrine therapy) in accordance with the National Comprehensive Cancer Network guidelines; * provision of informed consent of patients and their families. Exclusion Criteria: * Bilateral breast cancer; * inflammatory breast cancer; * pregnancy or lactation; * history of other cancers or chest radiotherapy.
๐Ÿ’Š

What it tests

  • PET-CT examination
  • Peripheral blood detection
๐Ÿ“

Where

2 sites
Shengjing Hospital of China Medical University
Shenyang, China
Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute
Shenyang, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy